Monitoring will be encompassed baseline assessments and follow-ups over subsequent months, evaluating clinical signs, Expanded Disability Status Scale (EDSS), cytokines, diffusion tensor imaging (DTI), functional MRI (fMRI), cognitive \& psychological evaluations, and flow cytometry for B cell markers. conditions: Multiple Sclerosis conditions: Secondary-Progressive Multiple Sclerosis conditions: Mesenchymal Stem Cells studyType: INTERVENTIONAL phases: PHASE1 allocation: NA interventionModel: SINGLE_GROUP interventionModelDescription: Open-label phase 1, single-center, pre-post comparison study primaryPurpose: TREATMENT masking: NONE count: 5 type: ACTUAL name: Allogenic placenta derived mesenchymal stem cells measure: Number of participants with Treatment-Emergent Adverse Events [Safety and Tolerability]. measure: Number of participants with a change in disability as measured by Expanded Disability Status Scale . measure: Number of participants with a change in cognitive function as measured by the Paced Auditory Serial Addition Test . measure: Number of participants with a change in cognitive performance as measured by Persian version of minimal assessment of cognitive function in MS battery. measure: Number of participants with a change in brain connectivity as measured by Functional magnetic resonance imaging . measure: Number of participants with a change in white matter integrity as measured by quantitative diffusion tensor imaging . measure: Number of participants with a change in processing and motor speed as assessed by the Symbol Digit Modalities Test . measure: Number of participants with evaluation of verbal learning and memory deficits as measured by the California Verbal Learning Test second edition . measure: Proportion of patients with change in CD20 / CD19 B cells surface markers measure: Biological Assessments including IL-10, IL-6, IL-17, and TNFα levels of cytokines. measure: Proportion of patients with change in T2 lesion volume on brain MRI. measure: Proportion of patients with change in brain volume on MRI. measure: Proportion of patients for assessment of visuospatial learning as measured by the Brief Visuospatial Memory Test-Revised . measure: Proportion of patients for assessment of visuospatial ability as measured by Judgment of Line Orientation Test . measure: Proportion of patients for evaluation of executive functions as measured by the Delis-Kaplan Executive Function System Sorting and descriptive tests. measure: Proportion of patients for measuring verbal fluency as measured by the Controlled Oral Word Association Test . measure: Proportion of patients for psychological assessment as measured by the validated Persian version of Symptom Checklist-90-Revised . measure: Proportion of patients for evaluation of fatigue as measured by was examined by the Persian version of Fatigue Severity Scale . measure: Proportion of patients for assessment of visuospatial ability as measured by the brief visuospatial memory test-revised test. measure: Proportion of patients for assessment of visuospatial ability as measured by the California Verbal Learning Test Second Edition test. sex: ALL minimumAge: 17 Years maximumAge: 45 Years stdAges: CHILD stdAges: ADULT facility: Tehran University of Medical Sciences,Tehran, Iran city: Tehran country: Iran, Islamic Republic of lat: 35.69439 lon: 51.42151 hasResults: False